Akebia Therapeutics Reports Third-Quarter Revenue of $36.9M, EPS Loss of $0.05
Third-quarter revenue fell 37% year over year as generic competition reduced Auryxia sales and Vafseo customers cut inventory. Akebia swung to a net loss from prior-year net income, citing lower revenue and higher research and development and restructuring costs.
Akebia Therapeutics’ third-quarter revenue fell 37% year over year as generic competition drove lower Auryxia sales and Vafseo customers reduced inventory. The company swung to a net loss from prior-year net income, reflecting lower revenue and higher research and development and restructuring cost…